Sionna Therapeutics, Inc. (SION)
7.18
+0.43
(+6.37%)
USD |
NASDAQ |
Sep 04, 16:00
7.215
+0.04
(+0.49%)
After-Hours: 20:00
Sionna Therapeutics Research and Development Expense (Quarterly) : 21.86M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 21.86M |
| March 31, 2026 | 18.96M |
| December 31, 2025 | 15.17M |
| September 30, 2025 | 16.04M |
| June 30, 2025 | 15.38M |
| March 31, 2025 | 13.67M |
| Date | Value |
|---|---|
| December 31, 2024 | 14.25M |
| September 30, 2024 | 24.58M |
| June 30, 2024 | 8.233M |
| March 31, 2024 | 10.22M |
| December 31, 2023 | 9.89M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Vertex Pharmaceuticals, Inc. | 993.80M |
| ACADIA Pharmaceuticals, Inc. | 81.56M |
| Immunic, Inc. | 25.93M |
| Alnylam Pharmaceuticals, Inc. | 413.13M |
| Anika Therapeutics, Inc. | 7.341M |